The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government ...

An investigational once-weekly oral antiretroviral therapy (ART) combination effectively maintained viral suppression in ...

PEPFAR has been one of the greatest success stories in global health, transforming the HIV response,” IAS President Beatriz Grinsztejn said. “Global advocacy played a crucial role in persuading US ...

The U.S. Senate has opened debate on a $9 billion rescission bill to claw back foreign aid and other funding not aligned with ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Findings from Kenya by CEMA at the International AIDS Society Conference on HIV ScienceRwanda, July 15, 2025-- The University of Nairobi, Center for Epidemiological Modelling and Analysis (CEMA), has ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

The World Health Organization (WHO) is recommending a twice-yearly injection of lenacapavir for prevention of HIV, according ...

The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...